This CME activity has reached its termination date and no longer offers continuing education credit. Please note that expired CME/CE activities may not contain the most up-to-date information available.
Click here to view our current activities in Oncology.
Managing a patient with colorectal cancer is increasingly a matter of individualized treatment, and it requires that the clinician have current knowledge not only of therapies, but also the underlying molecular biology. This complex topic is summarized in an on-demand, interactive webcast with a case study, presented by three noted clinical oncologists.
Jeffrey A. Meyerhardt, MD, MPH, of Harvard Medical School/Dana-Farber Cancer Institute, Alan Venook, MD, of UCSF, and Richard M. Goldberg, MD, of the University of North Carolina, review and summarize the pertinent scientific and therapeutic data.
Throughout, you will be provided with the opportunity to add your own input on appropriate management and compare your answers with those of your colleagues.
- Case Study of a 62-Year-Old Woman with Colorectal Cancer (CRC)
- Molecular Oncogenesis of CRC
- Primary Treatment with Adjuvant Chemotherapy
- Nonpharmacologic Strategies to Improve Outcomes in Nonmetastatic CRC
- Clinical Challenges of Comorbid Conditions
- Targeted Biologic Therapies in Metastatic CRC (Mechanisms, Efficacy, and Safety)
- Second-Line Therapies for Metastatic CRC
- Investigational Targeted Therapy Regimens
- Genetic Markers and Response to Biologic Therapies for CRC
This CME activity is directed to medical oncologists, gastroenterologists, and other healthcare professionals who provide care to patients with colorectal cancer.
The goal of this CME activity is to present the current and emerging first- and second-line treatments for stage III and metastatic colorectal cancer, with a focus on targeted therapies. The emphasis is on individualizing treatment, taking into consideration comorbid conditions, lifestyle, and disease-related factors. Potential outcomes will be illustrated through a case study.
- Evaluate the molecular basis of colorectal oncogenesis and relevant therapeutic targets to implement optimal colorectal cancer (CRC) treatment intervention.
- Utilize an understanding of the available CRC treatment options to improve patient selection, dosing, and response to therapy.
- Utilizing an understanding of the side effect and drug-drug interaction profiles of CRC treatment options, select the most appropriate treatment for improved patient outcomes.
- Customize the management of CRC to optimize CRC patient outcomes.
Statement of Accreditation
Projects In Knowledge is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Projects In Knowledge designates this educational activity for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contract for Mutual Responsibility in CME
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.
The Disclosure Policy of Projects In Knowledge requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials. For complete prescribing information on the products discussed during this CME activity, please see your current Physicians’ Desk Reference (PDR).
Richard M. Goldberg, MD, has received grant/research support from Pfizer Inc; and is a consultant for ALMAC Group Ltd, Amgen Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb, Genentech, Inc, Genomic Health, Inc, ImClone Systems Inc, Sanofi-Aventis, Taiho Pharmaceutical Company Ltd, and Yakult.
Jeffrey Meyerhardt, MD, MPH, is on the speakers bureau for Genentech, Inc and Pfizer Inc.
Alan P. Venook, MD, has received grant/research support from Genentech, Inc, Novartis Pharmaceuticals Corporation, and Pfizer Inc.
Peer Reviewer has received grant/research support from AstraZeneca; and has received speaker honoraria from the New York Academy of Sciences (NYAS).
Projects In Knowledge’s staff members have no significant relationships to disclose.
This activity will include a discussion of complex treatment regimens, some of which contain drugs that may not be FDA approved or that have off-label indications for use in patients with colorectal cancer.
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.
This CME activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the physician caring for the patient.
This independent CME activity is supported by educational grants from Genentech BioOncology, Novartis Pharmaceuticals Corporation, and Pfizer Inc.
Requires Flash 8 or higher
and high-speed internet